Want to see JAZZ full AI Analyst Report?
Top Page
Jazz Pharmaceuticals
(NASDAQ:JAZZ)
Select Model
Select Model
Rating:72Outperform
Price Target:
$251.00
▲(23.39% Upside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by strong cash-flow generation and sustained high gross margins, supporting financial resilience despite volatile net income. Technicals are constructive with a strong uptrend, though overbought signals raise short-term risk. Valuation appears reasonable with a ~10 P/E, and the latest earnings call was broadly positive with reaffirmed guidance, tempered by expected H2 sleep-market competition and some margin/mix pressure.
Positive Factors
Strong cash generation and free cash flow
Consistent operating cash flow and sizable free cash flow provide durable funding for R&D, commercial launches, and potential M&A without relying on equity issuance. Strong cash conversion cushions the business through earnings volatility and supports strategic optionality over the medium term.
Negative Factors
Substantial absolute debt burden
Despite improved leverage metrics, a ~$5.4B absolute debt load limits financial flexibility if cash flows weaken. Debt servicing and refinancing risk can constrain discretionary R&D or commercial investment and amplify sensitivity to interest rate or cash‑flow shocks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation and free cash flow
Consistent operating cash flow and sizable free cash flow provide durable funding for R&D, commercial launches, and potential M&A without relying on equity issuance. Strong cash conversion cushions the business through earnings volatility and supports strategic optionality over the medium term.
Read all positive factors
Jazz Pharmaceuticals Key Performance Indicators (KPIs)
Any
Neroscience Revenue Breakdown
Highlights revenue generated from neuroscience products, indicating the company's strength and focus in treating neurological disorders, and potential growth in this specialized market.
Highlights revenue generated from neuroscience products, indicating the company's strength and focus in treating neurological disorders, and potential growth in this specialized market.
Data provided by:
The Fly
The FlyJazz Pharmaceuticals (JAZZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.51B
Dividend YieldN/A
Average Volume (3M)911.77K
Price to Earnings (P/E)589.1
Beta (1Y)0.72
Revenue Growth9.20%
EPS Growth-94.01%
CountryUS
Employees2,890
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.41
Shares Outstanding62,817,627
10 Day Avg. Volume795,125
30 Day Avg. Volume911,775
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio9.05
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda32.76
Forecast
1Y Price Target
$259.87Price Target Upside27.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)25.36
Revenue Forecast (FY)$4.52B
Jazz Pharmaceuticals Business Overview & Revenue Model
Company Description
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idio...
How the Company Makes Money
Jazz Pharmaceuticals primarily makes money by selling prescription medicines, with revenue recognized from product sales to wholesalers, specialty pharmacies, hospitals, and other healthcare channels (net of rebates, discounts, returns, and other ...
Jazz Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial execution and substantial pipeline/regulatory progress that drove record Q1 revenue, robust product-level growth (notably oncology, Xywav and Epidiolex), solid cash generation and clear near-term catalysts (zanidatumab PDUFA, multiple interim readouts). Headline growth was partially boosted by an extra shipping week and FX effects, and management highlighted expected competitive dynamics in sleep and areas of margin and policy uncertainty. Overall, the positives (record revenue, high growth rates, cash strength, promising pivotal data and imminent regulatory milestones) outweigh the outlined risks and uncertainties.Positive Updates
Record First-Quarter Revenue and Strong Top-Line Growth
Reported highest-ever Q1 total revenues of approximately $1.07–$1.10 billion, representing more than 19% year-over-year growth; non-GAAP adjusted EPS of $6.34 and reaffirmation of full-year 2026 revenue guidance of $4.25 billion to $4.5 billion.
Negative Updates
Anticipated Competitive Pressure in Oxybate/Sleep Market
Management expects increased competition in H2 2026 including growth of high-sodium generics and potential entry of daytime wake-promoting agents, and expects declines in Xyrem and high-sodium authorized generic revenues as generics build volumes.
Read all updates
Q1-2026 Updates
Positive
Negative
Record First-Quarter Revenue and Strong Top-Line Growth
Reported highest-ever Q1 total revenues of approximately $1.07–$1.10 billion, representing more than 19% year-over-year growth; non-GAAP adjusted EPS of $6.34 and reaffirmation of full-year 2026 revenue guidance of $4.25 billion to $4.5 billion.
Read all positive updates
Company Guidance
Jazz reaffirmed full‑year 2026 non‑GAAP guidance of $4.25–$4.50 billion in revenue after a very strong start: Q1 record revenue of ~$1.07B (reported as $1.1B) and >19% YoY growth, non‑GAAP adjusted EPS of $6.34, and operating cash flow of $408M, with $2.9B in cash and investments at quarter‑end. Management said Q1 growth was led by oncology (+45%), Xywav (+18% to $408M; ~16,600 patients, ~425 net adds), Epidiolex (+15% to $250M; volume +16%), Zepzelca (+60% to $101M), Midevo ($41M; ~500 patients treated) and ZYHERA ($13M); Q1 benefitted from 13 shipping weeks (+~2 ppt) and FX (+~1.5 ppt). They noted a slight non‑GAAP gross margin decline, SG&A down ~$164M (but up ~$8M ex‑litigation), R&D up ~$13M, a modestly lower non‑GAAP tax rate, and reiterated assumptions of 2H headwinds in sleep (generic high‑sodium oxybates and potential new wake‑promoters), declining Xyrem/authorized‑generic revenues, and reduced second‑line Zepzelca use.Jazz Pharmaceuticals Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.44B | 4.27B | 4.07B | 3.83B | 3.66B | 3.09B |
| Gross Profit | 3.73B | 3.76B | 3.62B | 3.40B | 3.12B | 2.65B |
| EBITDA | 544.13M | 108.46M | 1.52B | 1.45B | 1.47B | 1.03B |
| Net Income | 29.49M | -356.15M | 560.12M | 414.83M | -224.06M | -328.95M |
Balance Sheet | ||||||
| Total Assets | 11.86B | 11.66B | 12.01B | 11.39B | 10.84B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.87B | 2.44B | 2.99B | 1.63B | 881.48M | 591.45M |
| Total Debt | 5.42B | 5.42B | 6.16B | 5.79B | 5.81B | 6.15B |
| Total Liabilities | 7.33B | 7.34B | 7.92B | 7.66B | 7.75B | 8.33B |
| Stockholders Equity | 4.53B | 4.32B | 4.09B | 3.74B | 3.09B | 3.97B |
Cash Flow | ||||||
| Free Cash Flow | 1.25B | 1.15B | 1.35B | 1.07B | 773.78M | 732.98M |
| Operating Cash Flow | 1.33B | 1.36B | 1.40B | 1.09B | 1.27B | 778.51M |
| Investing Cash Flow | -1.22B | -1.51B | -508.19M | -163.06M | -446.23M | -5.21B |
| Financing Cash Flow | -138.41M | -873.38M | 20.52M | -305.25M | -529.49M | 3.97B |
Jazz Pharmaceuticals Technical Analysis
Positive
203.42
Price Trends
231.01
Positive
209.50
Positive
182.71
Positive
Market Momentum
4.89
Negative
60.08
Neutral
82.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAZZ, the sentiment is Positive. The current price of 203.42 is below the 20-day moving average (MA) of 235.43, below the 50-day MA of 231.01, and above the 200-day MA of 182.71, indicating a bullish trend. The MACD of 4.89 indicates Negative momentum. The RSI at 60.08 is Neutral, neither overbought nor oversold. The STOCH value of 82.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JAZZ.
Jazz Pharmaceuticals Risk Analysis
Jazz Pharmaceuticals disclosed 47 risk factors in its most recent earnings report. Jazz Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jazz Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $9.33B | 26.13 | 126.27% | ― | 39.12% | -24.20% | |
73 Outperform | $10.01B | 203.29 | 7.50% | ― | 12.20% | -64.76% | |
72 Outperform | $15.51B | 589.15 | 0.71% | ― | 9.20% | -94.01% | |
70 Outperform | $11.14B | 100.25 | 5.49% | 0.54% | 0.17% | -15.73% | |
68 Neutral | $26.48B | -79.68 | -6.85% | ― | -89.16% | -84.69% | |
67 Neutral | $40.63B | -26.33 | -83.22% | ― | ― | -76.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JAZZ
Jazz Pharmaceuticals
243.82
133.55
121.11%
CORT
Corcept Therapeutics
91.88
20.00
27.82%
HALO
Halozyme
76.20
19.05
33.33%
TECH
Bio-Techne
71.30
17.49
32.49%
RVMD
Revolution Medicines
186.88
148.86
391.53%
ROIV
Roivant Sciences
35.97
24.61
216.64%
Jazz Pharmaceuticals Corporate Events
Executive/Board Changes
Jazz Pharmaceuticals announces planned board leadership transition
Neutral
May 29, 2026
On May 25, 2026, Jazz Pharmaceuticals disclosed that Anne O’Riordan, a Class III director whose term ends at the 2026 annual meeting, has notified the board that she will not stand for re-election. The company said her departure is not due t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.